What's Happening?
BioLab Holdings, a medical technology company based in Phoenix, has announced the publication of a study evaluating its Membrane Wrap™ for treating complex pressure ulcers. The study, published in the International Journal of Tissue Repair, assessed the effectiveness
of the Membrane Wrap™ in conjunction with standard care compared to standard care alone. The research involved 182 patients, with 91 receiving the Membrane Wrap™ treatment. Results indicated that 63.7% of patients treated with the Membrane Wrap™ showed healing or were healed, compared to 48.4% with standard care alone. This study is part of BioLab's broader strategy to generate clinical evidence for its products, aiming to improve patient outcomes.
Why It's Important?
The study's findings are significant as they provide evidence supporting the use of placental-based therapies in managing chronic pressure ulcers, a common issue among aging populations and those with chronic conditions. The Membrane Wrap™ could offer a more effective treatment option, potentially reducing healthcare costs and improving quality of life for patients. BioLab's commitment to clinical research underscores the importance of evidence-based approaches in advancing medical treatments and could influence future healthcare practices and policies.
What's Next?
BioLab is continuing its research efforts with ongoing trials, including the CAMPR-II trial for diabetic foot and venous leg ulcers, and the BIOMOHS trial, which is pending approval. These studies aim to further validate the efficacy of BioLab's products and expand their application in wound care. The company is also analyzing data from the CAMP RWE trial, which could provide additional insights into the effectiveness of their therapies.
